Secukinumab

Drug Profile

Secukinumab

Alternative Names: AIN-457; Cosentyx; Human anti-interleukin-17A monoclonal antibody; KB-03303A; NVP-AIN 457; Scapho

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Alcon; Novartis
  • Developer Icahn School of Medicine at Mount Sinai; Novartis
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriatic arthritis
  • Registered Ankylosing spondylitis; Pustular psoriasis
  • Phase III Psoriasis; Rheumatoid arthritis
  • Phase II Alopecia areata; Atopic dermatitis
  • Discontinued Asthma; Crohn's disease; Dry eyes; Multiple sclerosis; Polymyalgia rheumatica; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 06 Mar 2017 Efficacy data from pooled analysis of phase III trials presented at 2017 American Academy of Dermatology (AAD) Annual Meeting
  • 01 Feb 2017 Phase-III clinical trials in Plaque psoriasis in Hungary (SC) (EudraCT2016-000524-25)
  • 01 Feb 2017 Novartis plans a phase III trial for Juvenile-rheumatoid-arthritis (NCT03031782)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top